BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27758888)

  • 21. What do we know about the mechanisms of aromatase inhibitor resistance?
    Chen S; Masri S; Wang X; Phung S; Yuan YC; Wu X
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):232-40. PubMed ID: 17055257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells.
    Wang Y; Tzeng YT; Chang G; Wang X; Chen S
    Endocr Relat Cancer; 2020 Dec; 27(12):671-683. PubMed ID: 33112819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
    Magnani L; Frige G; Gadaleta RM; Corleone G; Fabris S; Kempe MH; Verschure PJ; Barozzi I; Vircillo V; Hong SP; Perone Y; Saini M; Trumpp A; Viale G; Neri A; Ali S; Colleoni MA; Pruneri G; Minucci S
    Nat Genet; 2017 Mar; 49(3):444-450. PubMed ID: 28112739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
    Bacci M; Giannoni E; Fearns A; Ribas R; Gao Q; Taddei ML; Pintus G; Dowsett M; Isacke CM; Martin LA; Chiarugi P; Morandi A
    Cancer Res; 2016 Mar; 76(6):1615-26. PubMed ID: 26795347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
    Mukhopadhyay KD; Liu Z; Bandyopadhyay A; Kirma NB; Tekmal RR; Wang S; Sun LZ
    PLoS One; 2015; 10(4):e0121136. PubMed ID: 25837259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
    Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    Miron L; Negură L; Peptanariu D; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
    Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of aromatase inhibitors.
    Hadfield KD; Newman WG
    Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of estrogen receptor alpha (ERα) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors.
    Koukouras D; Marioli DJ; Papadopoulos K; Adonakis GL; Armeni AK; Georgopoulos NA; Decavalas G
    Gynecol Endocrinol; 2012 Nov; 28(11):859-62. PubMed ID: 22799738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
    Hu Z; Song CG; Lu JS; Luo JM; Shen ZZ; Huang W; Shao ZM
    J Cancer Res Clin Oncol; 2007 Dec; 133(12):969-78. PubMed ID: 17562079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
    Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
    Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between the rs3802201 polymorphism of the lncRNA MIR2052HG gene and the risk of recurrent miscarriage in a Southern Chinese population.
    Mai H; Cai C; Lin K; Zhang L; Wang Y; He M; Qu Y; Xu Y; Fu L; Pi L; Zhou H; Zeng D; Che D; Zuo L
    J Clin Lab Anal; 2022 Jan; 36(1):e24167. PubMed ID: 34910326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer.
    Chen X; Luo R; Zhang Y; Ye S; Zeng X; Liu J; Huang D; Liu Y; Liu Q; Luo ML; Song E
    Nat Commun; 2022 Nov; 13(1):7160. PubMed ID: 36418319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New experimental models for aromatase inhibitor resistance.
    Chen S; Masri S; Hong Y; Wang X; Phung S; Yuan YC; Wu X
    J Steroid Biochem Mol Biol; 2007; 106(1-5):8-15. PubMed ID: 17611102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are all aromatase inhibitors the same? A review of the current evidence.
    Jänicke F
    Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.